November 15, 2021 | Volume 81 | Number 22

CANCER RESEARCH

TABLE OF CONTENTS

TABLE OF CONTENTS

TABLE OF CONTENTS

CORRECTION

ABOUT THE COVER

Various types of cancer overexpress oncogenic miRNAs, making them a potential therapeutic target. Next-generation chemically modified triplex peptide nucleic acid–based miR-155 inhibitors possess superior therapeutic efficacy compared with conventional full-length anti-miR-155. The cover depicts intratumoral treatment with the next-generation anti-miRNA-155 inhibitor. For details, see article by Dhuri and colleagues on page 5613.



doi: 10.1158/0008-5472.CAN-81-22-CVR